Evidence map›Paper›PMID 40507330›Full record

ArticleCancers2025

Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study.

Reshma Mahtani, Simon M Collin, Ziyu Tan, Chintal H Shah, Basirat Adeyemi, Sophie Davies, Ellie John, Gregory Vidal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Reshma MahtaniMiami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA.
Simon M CollinOncology Outcomes Research (O2R), Evidence Generation, Publications, and Partnerships, Global Medical Affairs, Oncology Business Unit, AstraZeneca, Cambridge CB2 0AA, UK.ORCID 0000-0002-1239-1681
Ziyu TanOncology Outcomes Research (O2R), Evidence Generation, Publications, and Partnerships, Global Medical Affairs, Oncology Business Unit, AstraZeneca, Cambridge CB2 0AA, UK.
Chintal H ShahOncology Outcomes Research (O2R), Evidence Generation, Publications, and Partnerships, Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA.ORCID 0000-0002-0225-507X
Basirat AdeyemiUS Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA.
Sophie DaviesGlobal Medical Affairs, Oncology Business Unit, AstraZeneca, Cambridge CB2 0AA, UK.
Ellie JohnGlobal Medical Affairs Payer Biometrics, Statistics, Oncology Business Unit, AstraZeneca, Cambridge CB2 0AA, UK.ORCID 0000-0002-9234-3275
Gregory VidalWest Cancer Center Research Institute and Lee S. Schwartzberg Research Center, Germantown, TN 38138, USA.

Funding

AstraZeneca and Daiichi Sankyo NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvant therapybreast cancerclinical outcomesearly stageHER2-positivehigh-riskneoadjuvant therapyobservational studysecondary datatreatment patterns

Identifiers

PMID40507330
PMCPMC12153779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.